glp-1 in pregnancy receptor agonists are increasingly used before pregnancy, but safety data have been limited., This meta-analysis pooled data from nearly 37,000 pregnancies and found no increased risk of major Discontinuing GLP-1 Receptor Agonist Use

Large self-insured employers have historically been passive consumers of PBM formulary decisions, primarily focused on the aggregate drug spend line in their benefits budget

31 thanks to a Defense Health Agency (DHA) decision that threatens both the health of those taking these medications and the overall health of the TRICARE For Life (TFL) benefit

The FDA requires extensive safety monitoring for all weight loss medications, and manufacturers must report adverse events, including cancer diagnoses

What to Look for in a Provider When considering options for support, choose a provider who has: Deep experience in metabolic medicine, obesity, and hormonal care

No significant correlations were observed for TFBUT at this time point